Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase Ib KEYNOTE-029 Study

Michael B. Atkins, F. Stephen Hodi, John A. Thompson, David F. McDermott, Wen Jen Hwu, Donald P. Lawrence, Nancy A. Dawson, Deborah J. Wong, Shailender Bhatia, Marihella James, Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F. Perini, Toni K. Choueiri, Antoni Ribas

Research output: Contribution to journal › Review article › peer-review

42 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase Ib KEYNOTE-029 Study'. Together they form a unique fingerprint.

Medicine & Life Sciences